hiv grade hbv tool
play

HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg - PowerPoint PPT Presentation

HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg Daten- bank HIVdb HIVdb Core Module HIV-SEQ Basis: Stanford HIVdb HIV-ALG 4/ 2008 Analysis flowchart Sequence data Mutation list Alignment on Pan- Genotype Consensus


  1. HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg

  2. Daten- bank HIVdb HIVdb Core Module HIV-SEQ Basis: Stanford HIVdb HIV-ALG 4/ 2008

  3. Analysis flowchart Sequence data Mutation list Alignment on Pan- Genotype Consensus Identification of available genes Identification of genotype and re-alignment on genotype specific consensus-sequence Identification of mutations Analysis of mutations based on the algorithm Detailled output Tabular output 4/ 2008

  4. Algorithm Specification Interface (ASI) � Rules based algorithms can be described in xml-format HBV-ruleset can be described in a format that is compatible to other algorithms 4/ 2008

  5. HBV drug resistance mutations 4/ 2008

  6. Algorithm RT-Inhibitors: Lamivudine Resistance Possible Resistance � 204ISV � 180M � 173L � 80VI Adefovir Resistance Possible Resistance � 236T � 233V � A181STV 4/ 2008

  7. Algorithmus Entecavir Resistance Possible Resistance � 204IV and 1 of (169T, 184AGILS, 202CGI, � 1 of (169T, 184AGILS, 202CGI, 250IV) � 204IV and 1 of (173L, 180M) 250IV) Comment: 204VI => A mutation M204VI alone only slightly impairs the susceptibility to entecavir, however the dose of entecavir should be increased according to the manufacturers instructions Tenofovir Resistance Possible Resistance � 194T 4/ 2008

  8. Possible Resistance � 180M Algorithm Telbivudine Resistance � 204ISV 4/ 2008

  9. � 1 of (137W, 141W, 144HA, 145R, 147S) HBs-antigen-escape Algorithm HBs-escape 4/ 2008

  10. Sequence input 4/ 2008

  11. Output of sequence length and genotype 4/ 2008

  12. Output of RT-Alignment 4/ 2008

  13. Output of HBsAg alignment 4/ 2008

  14. Analysis 4/ 2008

  15. Analysis 4/ 2008

  16. Analysis 4/ 2008

  17. Patient BN � HIV Coinfected � Therapy: TDF/ FTC, DRV, MVC � HIV-VL < 50 Cop./ ml � HBV-VL: 20.000.000 IU/ ml 4/ 2008

  18. Patient BN 4/ 2008

  19. HIV-GRADE e.V. � Thomas Berg, Medizinisches Labor Dr. Berg, Berlin � Patrick Braun, PZB Aachen � Martin Däumer, Institut für Immunologie und Genetik � Josef Eberle, Pettenkofer-Institut, München � Robert Ehret, PZB Aachen � Rolf Kaiser, Institut für Virologie, Köln � Klaus Korn, NRZ für Retroviren, Erlangen � Harm Müller, Fenner-Labor, Hamburg � Martin Stürmer, Institut für Medizinische Virologie, Frankfurt � Hauke Walter, NRZ für Retroviren, Erlangen � Eva Wolf, MUC Research München

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend